Top Markets
Coin of the day
Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696
Rang in Aktien #5731
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Aktienkurs
$29.86
Zuletzt synchronisiert: 2026-08-19
Marktkapitalisierung
$2.48B
Veränderung (1 Tag)
4.92%
Veränderung (1 Jahr)
502.82%
Land
TW
Handel Lin BioScience, Inc. (6696)

Kategorie

Dividendenrendite-Verlauf für Lin BioScience, Inc. (6696)
Dividendenrendite (TTM) von Lin BioScience, Inc. (Aktienkürzel: 6696) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Lin BioScience, Inc. (6696) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH